

2013年5月22日

各 位

会 社 名 第 一 三 共 株 式 会 社
代 表 者 代 表 取 締 役 社 長 中 山 讓 治
(コード番号 4568 東証・大証・名証各第1部)
問 合 せ 先 執 行 役 員 コーポレートコミュニケーション部長 石田 憲昭
TEL 報 道 関 係 者 の 皆 様 03-6225-1126
株 式 市 場 関 係 者 の 皆 様 03-6225-1125

ランバクシーの発表について

第一三共株式会社（本社：東京都中央区、以下「当社」）の連結子会社のランバクシー・ラボラトリーズ（本社：インド共和国ハリヤナ州グルガオン地区、以下「ランバクシー」）は、本日、別添の通り、過去の経営陣による行為を是正するための、ここ数年に亘る取組みについて、発表を行いましたのでお知らせいたします。

当社は、米国司法省（以下「DOJ」）および米国食品医薬品局（以下「FDA」）による調査の原因となった過去の行為を是正するためのこれらの取組みに対し、今後とも積極的に支援を続けてまいります。これらの取組みには、ランバクシーの経営、企業風土、オペレーション、コンプライアンスの大幅な刷新を含んでおります。

なお、当社は、ランバクシーの特定の以前の株主が、DOJ および FDA の調査に関する重要な情報を隠蔽したものと判断し、現在、法的な措置を講じております。

以 上

PRESS RELEASE

**RANBAXY HIGHLIGHTS IMPROVED BUSINESS AND QUALITY
ASSURANCE STANDARDS**

**DEDICATED TO PROVIDING SAFE AND EFFICACIOUS MEDICINES
GLOBALLY**

Gurgaon, India, May 22, 2013: Ranbaxy Laboratories Ltd. (RLL, NSE: RANBAXY, BSE: 500359) (“Ranbaxy”) today highlighted some of the major specific actions the Company has been taking in recent years to address certain conduct of the past and to ensure the safety and efficacy of all Ranbaxy products currently available in the global market. These actions include:

- Enhancing its compliance procedures and policies
- Upgrading its business and manufacturing processes
- Building a culture of accountability and excellence across all levels of the organization
- Complete reconstitution of the Board of Directors and Executive Management team

For additional information on the above, please visit www.ranbaxy.com

Arun Sawhney, CEO & Managing Director, Ranbaxy, stated, “Ranbaxy is a different company today. The steps we have taken over the recent years reflect the wide-ranging efforts of the current board and management to address certain conduct of the past and ensure that Ranbaxy moves forward with integrity and professionalism in everything we do. We are fully committed to upholding the high standards that patients, prescribers and all other stakeholders expect.”

Sawhney added, “All Ranbaxy products currently in the global market are safe and effective, and we remain focused on our philosophy of ‘Quality and Patients First.’ In the recent years we have made significant improvements in the way we conduct our business to ensure greater quality control and have made investments of over US\$ 300 million in our manufacturing facilities to install state-of-the-art technologies. We have also instituted a rigorous new Code of Conduct for all Ranbaxy employees, with clear accountability for compliance.”

Sawhney concluded, “Ranbaxy has successfully launched several new generic equivalents across the world recently, and maintains a robust pipeline of important new products as we look to build on our strong global portfolio of branded and generic prescription and OTC pharmaceuticals. We look forward to continuing to enrich lives globally with quality and affordable medicines.”

About Ranbaxy Laboratories Limited

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals, in developed and emerging markets many of which incorporate proprietary Novel Drug Delivery Systems (NDDS) and technologies, developed at its own labs. The company has further strengthened its focus on generics research and is increasingly working on more complex and specialty areas. Ranbaxy serves its customers in over 150 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 43 countries and manufacturing operations in 8 countries. Ranbaxy is a member of the Daiichi Sankyo Group. Through strategic in-licensing opportunities and its hybrid business model with Daiichi Sankyo, a leading global pharma innovator headquartered in Tokyo, Japan, Ranbaxy is introducing many innovator products in markets around the world, where it has a strong presence. This is in line with the company's commitment to increase penetration and improve access to medicines, across the globe. For more information, please visit www.ranbaxy.com.

Ranbaxy Contacts:

Koji Ogawa

Head - Corporate Services

email: koji.ogawa@ranbaxy.com

Tel: +91-124-4135620

Krishnan Ramalingam

General Manager, Corporate Communications

email: krishnan.ramalingam@ranbaxy.com

Mobile: 9810042540

Gaurav Chugh

Senior Manager - Corporate Communications

Email: gaurav.chugh@ranbaxy.com

Mobile: 9810471414